Plunkett W. Rationale for the design of combination therapies that are active in T-cell lymphomas?. Hematol Meeting Rep [Internet]. 2009 Jun. 10 [cited 2024 Dec. 22];2(13). Available from: https://www.pagepress.org/journals/hmr/article/view/498